2023 World Conference on Lung Cancer (Posters)-EP12.01. The Safety and Efficacy of Aumolertinib in Advanced NSCLC Patients with EGFRm Who were Intolerant to Osimertinib: A Retrospective Clinical Study

EP12.01. The Safety and Efficacy of Aumolertinib in Advanced NSCLC Patients with EGFRm Who were Intolerant to Osimertinib: A Retrospective Clinical Study - PDF(Abstract)

Back to course

Pdf Summary

A retrospective clinical study was conducted to evaluate the safety and efficacy of aumolertinib in advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations who were intolerant to osimertinib. The study included 23 NSCLC patients from multiple hospitals in Jiangxi Province, China. All patients had received osimertinib but switched to aumolertinib monotherapy due to adverse events caused by osimertinib. The primary endpoint of the study was to assess the safety of aumolertinib, while the secondary endpoint was progression-free survival (PFS).<br /><br />The study found that 12 out of 23 patients experienced grade 3 or higher adverse events with osimertinib, including rash, diarrhea, oral ulcers, interstitial pneumonia, decreased white blood cell count, decreased platelet count, liver injury, increased blood creatine phosphokinase (CPK) level, myocarditis, and paronychia. However, after switching to aumolertinib, there were no recurrences of adverse events in 21 patients, and the remaining two patients saw a downgrade in the severity of their adverse events.<br /><br />The duration of aumolertinib treatment was more than three months, and the median PFS was not reached. The study concludes that aumolertinib could be a feasible treatment option after full recovery from osimertinib-induced adverse events, potentially improving the quality of life for NSCLC patients. As the treatment of lung cancer shifts towards a chronic disease approach, patients prioritize a therapeutic schedule with good efficacy and few adverse events.<br /><br />In summary, this retrospective study demonstrates the safety and efficacy of aumolertinib as a switch treatment option for advanced NSCLC patients with EGFR mutations who are intolerant to osimertinib. The findings suggest that aumolertinib could provide a favorable therapeutic option with improved quality of life for patients.

Asset Subtitle

Longhua Sun

Meta Tag

Speaker Longhua Sun

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

retrospective study

clinical study

aumolertinib

non-small cell lung cancer

NSCLC

EGFR mutations

osimertinib intolerance

adverse events

safety

efficacy